Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: 4 - The Untold Story

What is ‘eye stroke’ and why has it been linked to weight loss injections?

The phrase “eye stroke” has recently appeared in news reports about a very rare side-effect of weight-loss injections. It’s not a formal medical diagnosis, but a shorthand used to describe a condition in which reduced blood flow damages the optic nerve and causes sudden vision loss.

The Conversation

Ozempic Controversy Deepens as FDA Accuses Novo Nordisk of Failing to Report Patient Deaths, One Linked To Suicide

Novo Nordisk faces FDA scrutiny for failing to report Ozempic-linked deaths, highlighting systemic issues in safety reporting. Learn about the implications for patient safety and ongoing legal challenges.

International Business Times UK

Label unhealthy foods, weight drug boss tells Australia

Workplace health checks, clearer labels on unhealthy foods and better education would help Australia reduce high rates of obesity, a drug company chief says.

AAP

From analysis to the latest developments in health,
read the most diverse news in one place.

Illegal weight loss jabs being sold in London pubs and fish and chip shops, report claims

It is alleged beauticians and personal trainers are exploiting soaring interest in weight loss jabs

Evening Standard

Feds warn Ozempic and Wegovy maker over failure to report side-effects from weight-loss drugs

Officials wrote that Novo Nordisk had failed to failed to report ‘serious and unexpected’ adverse drug experiences

The Independent UK

Weight loss jab ‘may carry higher risk of sudden sight loss’ as new warning issued

Wegovy is approved on the NHS to help people lose weight in higher doses

The Independent UK

Wegovy users have five times greater risk of sudden sight loss than Ozempic users, study finds

‘Eye strokes’ that reduce blood flow to optic nerve likely to be side-effect of active ingredient semaglutide, says author

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal

Hims & Hers shares surged 46% after partnering with Novo Nordisk to offer FDA-approved Ozempic and Wegovy, moving away from compounded GLP-1 alternatives.

MarketBeat

Novo Nordisk and Hims & Hers Turn Patent Dispute Into Business Opportunity

Novo Nordisk drops its lawsuit against Hims & Hers as the companies partner to offer FDA-approved Wegovy and Ozempic through the telehealth platform.

International Business Times

Stocks Recover as Oil Retreats From $119: Stock Market Today

How high the price of crude oil rises and how long it stays there are critical questions for market participants and policymakers alike.

Kiplinger

Hims & Hers Stock Is Challenging Its 50-Day Moving Average. Should You Bet on a Turnaround Here?

Hims & Hers shares soared as Novo Nordisk dropped its GLP-1 lawsuit. But there’s reason to still sell HIMS stock today. Find out more!

Barchart

Novo Nordisk drops lawsuit over weight loss medications, enters collaboration with online pharmacy

The news sent shares of Hims & Hers Health Inc. soaring by more than 40% in Monday morning trading

The Independent UK

Novo Nordisk announces plan to cut Ozempic and Wegovy prices up to 50 percent

One in eight Americans are taking weight loss drugs like Ozempic and Wegovy

The Independent UK

Novo Nordisk Stock Is Deeply Oversold on Weight Loss Drug Fail. Should You Buy the Dip?

Novo Nordisk stock tanks as CagriSema appears inferior to Eli Lilly’s competing weight-loss drug in a late-stage trial. But NVO shares are still worth buying at current levels.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is labelled ‘obsolete’

Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectations

MarketBeat

Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside

HIMS is down 48% in the past month following a Novo Nordisk lawsuit. But, analysts expect record revenue when the company reports earnings this month.

Barchart

As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock?

Hims & Hers shares crater as Novo Nordisk files a lawsuit against the telehealth firm. BofA analysts see significant further downside in HIMS stock.

The Guardian - US

Trump Rx prescription drug site ‘not a solution’ for many patients, experts say

New website lists only limited number of medications – and many of them cost less in generic form elsewhere

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Super Bowl ads try to overcome tough times with health, caring and the usual laughs

At a difficult time for America, Super Bowl advertisers are asking viewers to take care of themselves and others — and maybe even crack a smile

The Independent UK

Hims & Hers drops plan for knockoff of Novo Nordisk's new Wegovy weight loss pill

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug

The Independent UK

Experts warn against ‘worrying’ rise in dangerous weight-loss ‘jab hacks’

Almost half of the 1.6 million people using weight-loss jabs admit to either trying dosing ‘hacks’, or turning to unlicensed drugs and sellers

The Independent UK

Trump and Dr. Oz bring ‘As Seen on TV’ vibes to Rx coupon portal for cheap ‘fat drugs’

ANALYSIS: The president’s latest gambit at health care affordability, TrumpRx, isn’t the panacea he promised for access to low-cost GLP-1 drugs like Wegovy, Ozempic and Mounjaro— but some experts tell Andrew Feinberg that the effort should not be dismissed

Euronews

US health company launches weight-loss pill that Novo Nordisk calls an 'untested knockoff'

The American telehealth company announced the launch of a compounded weight-loss pill for €41, drawing criticism from Novo Nordisk, the Danish company behind the weight-loss drug Wegovy, which called the product an “untested knockoff.”

inkl

Novo Nordisk's APAC Supply Chain Guru: How Muhammad Shahid's AI-Powered Forecasting Cut Planning Cycles by 25% and Supercharged Pharma Delivery

Today’s pharmaceutical supply chains are under constant pressure. Evolving demands, complex regulations, and razor-thin margins mean one wrong forecast can ripple into shortages across entire regions.

Axios

TrumpRx is live. Here's what the website shows

The site is a key part of President Trump's efforts to lower health costs but isn't expected to significantly affect drug prices.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.